Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 7;11(8):1129.
doi: 10.3390/cancers11081129.

High Level Expression of MHC-II in HPV+ Head and Neck Cancers Suggests that Tumor Epithelial Cells Serve an Important Role as Accessory Antigen Presenting Cells

Affiliations

High Level Expression of MHC-II in HPV+ Head and Neck Cancers Suggests that Tumor Epithelial Cells Serve an Important Role as Accessory Antigen Presenting Cells

Steven F Gameiro et al. Cancers (Basel). .

Abstract

High-risk human papillomaviruses (HPVs) are responsible for a subset of head and neck squamous cell carcinomas (HNSCC). Expression of class II major histocompatibility complex (MHC-II) is associated with antigen presenting cells (APCs). During inflammation, epithelial cells can be induced to express MHC-II and function as accessory APCs. Utilizing RNA-seq data from over 500 HNSCC patients from The Cancer Genome Atlas, we determined the impact of HPV-status on the expression of MHC-II genes and related genes involved in their regulation, antigen presentation, and T-cell co-stimulation. Expression of virtually all MHC-II genes was significantly upregulated in HPV+ carcinomas compared to HPV- or normal control tissue. Similarly, genes that encode products involved in antigen presentation were also significantly upregulated in the HPV+ cohort. In addition, the expression of CIITA and RFX5-regulators of MHC-II-were significantly upregulated in HPV+ tumors. This coordinated upregulation of MHC-II genes was correlated with higher intratumoral levels of interferon-gamma in HPV+ carcinomas. Furthermore, genes that encode various co-stimulatory molecules involved in T-cell activation and survival were also significantly upregulated in HPV+ tumors. Collectively, these results suggest a previously unappreciated role for epithelial cells in antigen presentation that functionally contributes to the highly immunogenic tumor microenvironment observed in HPV+ HNSCC.

Keywords: MHC-II; T-cell; antigen presentation; co-stimulatory molecules; head and neck carcinoma; human papillomavirus; major histocompatibility complex; survival signals.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Expression of classical class II major histocompatibility complex (MHC-II) α- and β-chain genes in head and neck squamous cell carcinomas stratified by high-risk human papillomaviruses (HPV)-status. RNA-Seq by Expectation Maximization (RSEM)-normalized RNA-seq data for the indicated MHC-II genes was extracted from The Cancer Genome Atlas (TCGA) database for the head and neck squamous cell carcinoma (HNSC) cohort for HPV+, HPV−, and normal control tissues. Numbers in brackets refer to the number of samples included in each analysis. Statistical analysis was performed using a two-tailed non-parametric Mann–Whitney U test. ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns—not significant.
Figure 2
Figure 2
Expression of the invariant chain and MHC class II-like genes in head and neck carcinomas stratified by HPV-status. RSEM normalized RNA-seq data for the indicated genes involved in MHC-II-dependent antigen processing and presentation was extracted from the TCGA database for the HNSC cohort for HPV+, HPV−, and normal control tissues. Numbers in brackets refer to the number of samples included in each analysis. Statistical analysis was performed using a two-tailed non-parametric Mann–Whitney U test. ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns—not significant.
Figure 3
Figure 3
Expression of class II major histocompatibility complex transactivator (CIITA), regulatory factor X5 (RFX5), and interferon-gamma (IFNG) mRNA in head and neck carcinomas stratified by HPV-status. RSEM normalized RNA-seq data for the CIITA, RFX5, and IFNG genes were extracted from the TCGA database for the HNSC cohort for HPV+, HPV−, and normal control tissues. Numbers in brackets refer to the number of samples included in each analysis. Statistical analysis was performed using a two-tailed non-parametric Mann–Whitney U test. ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns—not significant.
Figure 4
Figure 4
Correlation matrix of genes involved in the MHC-II antigen presentation pathway in head and neck carcinomas stratified by HPV-status. RSEM normalized RNA-seq data for the genes listed above were extracted from the TCGA database for the HNSC cohort for HPV+ (upper triangle) and HPV− samples (lower triangle). Pairwise spearman correlation was performed followed by hierarchical clustering to group based on correlation. Number in boxes indicate Spearman’s rank correlation coefficient of analyzed gene pairs.
Figure 5
Figure 5
Expression of genes that encode for T-cell co-stimulatory molecules in head and neck carcinomas stratified by HPV-status. RSEM normalized RNA-seq data for genes that encode T-cell specific co-stimulatory molecules was extracted from the TCGA database for the HNSC cohort for HPV+, HPV−, and normal control tissues. Statistical analysis was performed using a two-tailed non-parametric Mann–Whitney U test. Numbers in brackets refer to the number of samples included in each analysis. **** p ≤ 0.0001, ns—not significant.
Figure 6
Figure 6
Expression of inducible T-cell survival signal molecules in head and neck carcinomas stratified by HPV-status. RSEM normalized RNA-seq data for inducible genes that encode for T-cell survival molecules was extracted from the TCGA database for the HNSC cohort for HPV+, HPV−, and normal control tissues. Statistical analysis was performed using a two-tailed non-parametric Mann–Whitney U test. Numbers in brackets refer to the number of samples included in each analysis. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns—not significant.

References

    1. Doorbar J., Egawa N., Griffin H., Kranjec C., Murakami I. Human Papillomavirus Molecular Biology and Disease Association. Rev. Med. Virol. 2015;25(Suppl. 1):2–23. doi: 10.1002/rmv.1822. - DOI - PMC - PubMed
    1. Forman D., de Martel C., Lacey C.J., Soerjomataram I., Lortet-Tieulent J., Bruni L., Vignat J., Ferlay J., Bray F., Franceschi S., et al. Global Burden of Human Papillomavirus and Related Diseases. Vaccine. 2012;30(Suppl. 5):F12–F23. doi: 10.1016/j.vaccine.2012.07.055. - DOI - PubMed
    1. Gillison M.L., Koch W.M., Capone R.B., Spafford M., Westra W.H., Wu L., Zahurak M.L., Daniel R.W., Viglione M., Symer D.E., et al. Evidence for a Causal Association between Human Papillomavirus and a Subset of Head and Neck Cancers. J. Natl. Cancer Inst. 2000;92:709–720. doi: 10.1093/jnci/92.9.709. - DOI - PubMed
    1. Syrjänen S. Human Papillomavirus (HPV) in Head and Neck Cancer. J. Clin. Virol. 2005;32(Suppl. 1):S59–S66. - PubMed
    1. Gillison M.L., Castellsagué X., Chaturvedi A., Goodman M.T., Snijders P., Tommasino M., Arbyn M., Franceschi S. Eurogin Roadmap: Comparative Epidemiology of HPV Infection and Associated Cancers of the Head and Neck and Cervix. Int. J. Cancer. 2013;134:497–507. doi: 10.1002/ijc.28201. - DOI - PubMed